3/18
07:00 am
kalv
KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026
Medium
Report
KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026
3/4
07:00 am
kalv
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/2
07:13 am
kalv
KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat) [Yahoo! Finance]
Low
Report
KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat) [Yahoo! Finance]
3/2
07:00 am
kalv
KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)
Low
Report
KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)
2/25
07:00 am
kalv
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
Low
Report
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
2/18
07:00 am
kalv
KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline
Low
Report
KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline
2/17
09:36 am
kalv
Most shorted stocks with up to $2B market cap as of mid-February [Seeking Alpha]
Low
Report
Most shorted stocks with up to $2B market cap as of mid-February [Seeking Alpha]
2/12
07:16 am
kalv
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting [Yahoo! Finance]
Low
Report
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting [Yahoo! Finance]
2/12
07:00 am
kalv
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
Low
Report
KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
2/11
03:46 pm
kalv
KalVista: Next Stage Of Growth For EKTERLY Lies With Pediatric Label Expansion [Seeking Alpha]
Low
Report
KalVista: Next Stage Of Growth For EKTERLY Lies With Pediatric Label Expansion [Seeking Alpha]
2/3
07:00 am
kalv
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/2
03:51 pm
kalv
TD Cowen Bullish on KalVista Pharmaceuticals, Inc. (KALV) Ahead of Q4 Results [Yahoo! Finance]
Low
Report
TD Cowen Bullish on KalVista Pharmaceuticals, Inc. (KALV) Ahead of Q4 Results [Yahoo! Finance]
1/24
05:09 am
kalv
KalVista Pharmaceuticals (NASDAQ:KALV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
KalVista Pharmaceuticals (NASDAQ:KALV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/9
08:02 am
kalv
KalVista Pharmaceuticals (NASDAQ:KALV) had its price target raised by analysts at HC Wainwright from $27.00 to $37.00. They now have a "buy" rating on the stock.
Medium
Report
KalVista Pharmaceuticals (NASDAQ:KALV) had its price target raised by analysts at HC Wainwright from $27.00 to $37.00. They now have a "buy" rating on the stock.
1/8
04:27 pm
kalv
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results [Yahoo! Finance]
Medium
Report
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results [Yahoo! Finance]
1/8
04:05 pm
kalv
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results
Medium
Report
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results
1/6
08:00 am
kalv
KalVista Pharmaceuticals (NASDAQ:KALV) had its price target raised by analysts at Needham & Company LLC from $28.00 to $32.00. They now have a "buy" rating on the stock.
Low
Report
KalVista Pharmaceuticals (NASDAQ:KALV) had its price target raised by analysts at Needham & Company LLC from $28.00 to $32.00. They now have a "buy" rating on the stock.